TG Therapeutics

Tg Therapeutics

Biotechnology, 2 Gansevoort St Fl 9, New York, 10014, United States, 201-500 Employees

tgtherapeutics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +18*********

Who is TG THERAPEUTICS

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline in...

Read More

map
  • 2 Gansevoort St Fl 9, New York, New York, 10014, United States Headquarters: 2 Gansevoort St Fl 9, New York, New York, 10014, United States
  • 2011 Date Founded: 2011
  • 201-500 Employees: 201-500
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 511210 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from TG THERAPEUTICS

TG Therapeutics Org Chart and Mapping

Employees

Amy Prins

Associate Director, Key Accounts

Robin Mattox

Clincal Research Associate

Juan Garcia

Associate Director, Key Accounts

Susan Chiosso

Associate Director, Key Accounts

Scott Lukasek

Director Market Access Account Management

Courtney Marszalek

Clinical and Tmf Operations, Site Operations Lead

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding TG Therapeutics

Answer: TG Therapeutics's headquarters are located at 2 Gansevoort St Fl 9, New York, 10014, United States

Answer: TG Therapeutics's phone number is +18*********

Answer: TG Therapeutics's official website is https://tgtherapeutics.com

Answer: TG Therapeutics's revenue is $1 Million to $5 Million

Answer: TG Therapeutics's SIC: 2834

Answer: TG Therapeutics's NAICS: 511210

Answer: TG Therapeutics has 201-500 employees

Answer: TG Therapeutics is in Biotechnology

Answer: TG Therapeutics contact info: Phone number: +18********* Website: https://tgtherapeutics.com

Answer: TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access